Eyes with neovascular age-related macular degeneration treated with aflibercept were almost three times more likely to be weaned off treatment after 1 year compared with those treated with bevacizumab, according to a study.
“We confirm that using aflibercept can result in a longer treatment interval and fewer injections using a treat-and-extend approach compared to bevacizumab,” the study authors wrote. “Conversely, while the number of treatments was slightly higher for the bevacizumab group, the final [central subfield thickness] and the final visual acuity was similar at 1